Associated Papers
Discovery of APS03118, a Potent and Selective Next-Generation RET Inhibitor with a Novel Kinase Hinge Scaffold.
Zhong J et al.
Journal of Medicinal Chemistry, 2025
Targeting RET in medullary thyroid cancer.
Newbold K et al.
Endocrine-related Cancer, 2025
Design and Discovery of Novel Selective RET Inhibitors with High Central Nervous System Penetration, Enhanced Pharmacokinetics, and Pharmacodynamics.
Wang X et al.
Journal of Medicinal Chemistry, 2025
Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D.
Zheng Q et al.
Nature Chemical Biology, 2024
38443470 (PubMed )
Supplement: 41589_2024_1565_MOESM1_ESM.pdf
RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.
Chen MF et al.
Drugs, 2024
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers.
Rotow J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.
Ali F et al.
Archives of Pharmacal Research, 2022
Precision oncology for RET-related tumors.
Verrienti A et al.
Frontiers in Oncology, 2022
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions.
Kim J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2021
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.
Saha D et al.
Journal of Medicinal Chemistry, 2021
The importance of the RET gene in thyroid cancer and therapeutic implications.
Salvatore D et al.
Nature Reviews. Endocrinology, 2021
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.
Subbiah V et al.
Cancer Discovery, 2018
Select a paper to view details